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Abstract
Background: γ-Aminobutyric acid type A (GABAA) receptors provide the main inhibitory control
in the brain. Their heterogeneity may make it possible to precisely target drug effects to selected
neuronal populations. In situ hybridization using rat brain sections has revealed a unique expression
of GABAA receptor ε and θ subunit transcripts in the locus coeruleus, where they are accompanied
at least by α3, α2, β1 and β3 subunits. Here, we studied the pharmacology of the human α3β1,
α3β1ε, α3β1θ and α3β1εθ receptor subtypes expressed in Xenopus oocytes and compared them
with the γ2 subunit-containing receptors.
Results: The GABA sensitivites and effects of several positive modulators of GABAA receptors
were studied in the absence and the presence of EC25 GABA using the two-electrode voltage-clamp
method. We found 100-fold differences in GABA sensitivity between the receptors, α3β1ε subtype
being the most sensitive and α3β1γ2 the least sensitive. Also gaboxadol dose-response curves
followed the same sensitivity rank order, with EC50 values being 72 and 411 µM for α3β1ε and
α3β1γ2 subtypes, respectively. In the presence of EC25 GABA, introduction of the ε subunit to the
receptor complex resulted in diminished modulatory effects by etomidate, propofol, pregnanolone
and flurazepam, but not by pentobarbital. Furthermore, the α3β1ε subtype displayed picrotoxin-
sensitive spontaneous activity. The θ subunit-containing receptors were efficiently potentiated by
the anesthetic etomidate, suggesting that θ subunit could bring the properties of β2 or β3 subunits
to the receptor complex.
Conclusion: The ε and θ subunits bring additional features to α3β1 GABAA receptors. These
receptor subtypes may constitute as novel drug targets in selected brain regions, e.g., in the
brainstem locus coeruleus nuclei.
Background
The A-type receptors for γ-aminobutyric acid (GABAA)
mediate the majority of fast inhibitory transmission in the
mammalian central nervous system. Many clinically
important drugs including benzodiazepines, barbiturates
and general anesthetics act as positive allosteric modula-
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tors of this receptor [1-3]. GABAA receptors are pentameric
ligand-gated ion-channels, composed of subunits from
many subunit classes: α1–6, β1–3, γ1–3, δ, ε, θ, π, and ρ1–
3. This produces a great heterogeneity in the receptor
structures and receptor properties. The main receptor pop-
ulation containing the α1 subunit is responsible for only
some, but not all, behavioral and physiological effects of
GABAA  receptors and, most importantly, the animals
devoid of the α1 subunits survive without dramatic
abnormalities [4-6]. Therefore, it is possible that minor
subtypes are also relevant in physiology and as pharmaco-
logical targets.
Here, we focused our study on minor populations of
novel ε and θ subunit-containing GABAA receptors. These
subunits are enriched in several discrete nuclei, most
remarkably in the bilateral brainstem nucleus locus coer-
uleus (LC) [7]. The ε and θ subunit genes are clustered
with the α3 subunit gene in the chromosome Xq28 [1],
suggesting a common ancestry with the three other β-α-γ
GABAA receptor subunit gene clusters in other chromo-
somes, although the θ and ε subunits have diverged
remarkably from β- and γ-like sequences [8,9]. The in situ
hybridization signals of rat brain sections have shown
that the LC neurons express among the α subunits, the α3
and α2 subunit mRNAs, but not those of α1, α4, α5 or α6
[7,10-12], among the β subunits, the β1 and β3 subunit
mRNAs [13], but none of the γ1–3 mRNAs are clearly
enriched in the LC neurons. In contrast to the expression
profiles of the most GABAA receptor subunits, the ε and θ
subunit mRNAs are strongly enriched in the LC neurons
[12]. These expression profiles suggest a likely existence at
least of α3β1θ,  α3β1ε and α3β1 receptor populations
among the LC GABAA receptors, with additional roles of
α2 and β3 subunits in either replacing the α3 and β1 and/
or perhaps co-assembling with them (see [14]).
The θ subunit has the highest sequence identity (about
50%) with the β1 subunit [15]. It should hypothetically
form functional receptors with α and β or α and γ subu-
nits, but in practice it may not form functional receptors
when coexpressed with an α subunit or an α and β subu-
nit as the αβθ combination failed to respond to GABA
[15]. Thus, only little is known about the pharmacological
properties of the θ subunit, and its role has not been sat-
isfactorily studied in different receptor subunit combina-
tions.
The ε subunit is more related to the γ subunits [16,17].
The effect of the ε subunits on the properties of GABAA
receptor subtypes has been studied only in a few receptor
subtypes, mostly in α1 subunit-containing receptors. The
ε subunit-containing receptors display insensitivity to
benzodiazepines and reduced efficacy for anesthetics,
spontaneous channel openings, sensitivity to picrotoxin,
rapid or more extensive desensitization, and this subunit
has abolished the outward rectification in recombinant
receptors [17-20].
The LC is the largest noradrenergic nucleus with many
projections innervating major levels of neuraxis. It plays
an important role in the regulation of anxiety states, vigi-
lance, attention and memory functions [21]. It has been
shown that 50 % of the nerve terminals in the LC can
accumulate [3H]GABA and that the LC neurons contain
glutamic acid decarboxylase, the GABA biosynthetic
enzyme [11,22]. The LC harbors a unique repertoire of
GABAA receptors due to the expression of ε and θ subunits.
This report describes a characterization of recombinant
α3β1θ/ε receptors that most likely form major GABAA
receptor populations in the LC neurons.
Results
GABA-site sensitivity of recombinant human GABAA 
receptors expressed in Xenopus oocytes
GABA elicited inward currents in α3β1, α3β1γ2s, α3β1θ,
α3β1ε and α3β1εθ GABAA receptors that were well distin-
guished from the baseline, whereas no currents were
detected in the α3θε combination or the dimer α3θ com-
bination (data not shown). The GABA concentration-
response curves are depicted in Fig. 1A. Currents were nor-
malized to the maximal peak currents induced by GABA
(Imax). GABA concentrations producing 50 % of the maxi-
mum efficacy (EC50) varied significantly between the
receptor subtypes. The α3β1ε receptors had the highest
GABA sensitivity (EC50 2.3 µM), being 25-fold higher than
in α3β1 and α3β1θ receptors and almost 100-fold higher
than in α3β1γ2 receptors (200 µM). The GABA sensitivity
of α3β1θ receptors was not different from that of α3β1,
while the addition of ε subunit significantly increased
GABA sensitivity and the addition of γ2 reduced it. When
both ε and θ subunits were co-injected, the oocytes had
similar EC50 values for GABA as the α3β1 receptors.
The potency of gaboxadol, a partial agonist of the GABA
site [23], at all tested receptor subtypes was lower than
that of GABA (Fig. 1B). Gaboxadol had the highest
potency at the α3β1ε receptor (EC50 = 72 µM), followed
by α3β1 (139 µM), α3β1εθ (165 µM), α3β1θ (224 µM)
and α3β1γ2 receptors (411 µM). Since different batches of
oocytes were used in Fig. 1, maximal currents induced by
GABA and gaboxadol could not be compared. When 1
mM concentrations of GABA and gaboxadol were individ-
ually applied to the same oocytes, the gaboxadol-evoked
currents were only about 50% of the corresponding GABA
currents (data not shown), suggesting that gaboxadol is a
partial agonist at these receptor subtypes. More specifi-
cally in α3β1ε receptors, in which 1 mM concentrations of
both agonists saturate the receptor (Fig. 1), gaboxadol-
induced currents were 34 ± 2 % of the GABA currents (n =BMC Pharmacology 2006, 6:1 http://www.biomedcentral.com/1471-2210/6/1
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Responses to GABA site ligands Figure 1
Responses to GABA site ligands. GABA and gaboxadol 
sensitivities of recombinant α3β1, α3β1γ2, α3β1θ, α3β1ε 
and α3β1θε GABAA receptors expressed in Xenopus 
oocytes. A. The values for currents induced by various 
GABA concentrations are given as means ± standard errors 
(n = 8 for α3β1, n = 6 for α3β1γ2, n = 7 for α3β1θ; n = 6 for 
α3β1ε and n = 7 for α3β1θε receptors). GABA dose-
response curves were obtained by non-linear regression fits 
and GABA EC50 values were calculated for individual cells, 
being 55 ± 6 µM for α3β1 receptors, 200 ± 38 µM for 
α3β1γ2 (p < 0.01, unpaired t-test from α3β1), 2.3 ± 0.5 µM 
for α3β1ε (p < 0.001 from α3β1) and 81 ± 18 µM for α3β1θ 
(p > 0.05) and 35 ± 9 µM for α3β1θε receptors. Maximal 
currents elicited by GABA were 1.5 ± 0.9 µA for α3β1, 2.2 ± 
0.5 µA for α3β1γ2, 1.2 ± 0.3 µA for α3β1θ; 1.2 ± 1.0 µA for 
α3β1ε and 0.9 ± 0.4 µA for α3β1θε combinations. B. Gabox-
adol-induced currents are given as means ± standard errors 
(n = 7 for α3β1, n = 5 for α3β1γ2, n = 4 for α3β1θ; n = 5 for 
α3β1ε and n = 4 for α3β1θε receptors). Gaboxadol dose-
response curves were obtained by non-linear regression fits 
and the EC50 values were calculated for individual cells, being 
139 ± 19 µM for α3β1 receptors, 411 ± 13 µM for α3β1γ2 
(p < 0.05, unpaired t-test from α3β1),72 ± 5 µM for α3β1ε 
(p > 0.05 from α3β1), 224 ± 20 µM for α3β1θ (p > 0.05) and 
165 ± 19 µM for α3β1θε receptors. Maximal currents elic-
ited by gaboxadol were 2.5 ± 0.9 µA for α3β1, 1.2 ± 0.5 µA 
for α3β1γ2, 0.55 ± 0.2 µA for α3β1θ, 1.0 ± 0.4 µA for α3β1ε 
and 0.8 ± 0.3 µA for α3β1θε combinations.
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3) and both agonists applied simultaneously evoked a
current that was 90 ± 1 % of the GABA current alone.
ε subunit-containing receptors display leakage currents 
that can be blocked with picrotoxin
Recombinant  α3β1ε receptors exhibited spontaneous
activity, which could be seen by outward currents during
application of 100 µM picrotoxin, the GABAA receptor
channel blocker, and often by the continuous drift of the
baseline. Figure 2 illustrates the effect of picrotoxin (panel
A) and compares its amplitude to the inward currents
induced by 1.5 µM GABA (panel B).
θ subunit confers high efficacy for etomidate
In the presence of 100 µM etomidate, GABA-induced cur-
rents were 159 ± 6 % of the control GABA response for
α3β1 (mean ± standard error, n = 5), 176 ± 9 % for
α3β1γ2 (n = 5), 298 ± 18 % for α3β1θ (n = 6), 122 ± 5 %
for α3β1ε (n = 10) and 186 ± 7 % for α3β1εθ (n = 4)
receptors (Fig. 3), indicating that the α3β1θ receptors
were potentiated by etomidate the most (p < 0.001, Dun-
nett's test) and the α3β1ε receptors the least (p < 0.05).
Nonlinear regression fit of etomidate potentiation of
GABA-induced currents revealed that etomidate had
higher efficacy in α3β1θ than α3β1γ2 receptors (maximal
potentiation 364 ± 43 vs. 222 ± 15 % of the control GABA
response, respectively, p < 0.01, unpaired t-test), but there
was no drastic difference in etomidate potency (EC50 ~ 50
µM in both combinations). In α3β1εθ receptors, the effi-
cacy of etomidate was clearly reduced from that for α3β1θ
receptors.
θ and γ2 subunits enhance propofol efficacy
In the presence of 100 µM propofol, GABA-induced cur-
rents were 153 ± 4 % of the control GABA response for
α3β1 (mean ± standard error, n = 5), 269 ± 18 % for
α3β1γ2 (n = 7), 244 ± 16 % for α3β1θ (n = 5), 126 ± 9 %
for α3β1ε (n = 6) and 161 ± 6 % for α3β1εθ (n = 3) recep-
tors (Fig. 4), indicating that both γ2 and θ subunit-con-
taining receptors were more potentiated by propofol than
α3β1 combination (p < 0.001 for both combinations vs.
α3β1, Dunnett's test). The α3β1ε receptors were hardly
potentiated at all, but addition of the θ subunit to this
combination increased the efficacy. Nonlinear regression
fit of propofol potentiation of GABA-induced currents
yielded a similar potency (EC50 = 20 µM) and maximal
potentiation for α3β1γ2 and α3β1θ receptors (297 ± 15
and 257 ± 12 %, respectively).
ε and θ subunits reduce neurosteroid potency
In the presence of 1 µM pregnanolone, GABA-induced
currents were 152 ± 5 % of the control GABA response for
α3β1 (mean ± standard error, n = 6), 177 ± 6 % for
α3β1γ2 (n = 5), 135 ± 4 % for α3β1θ (n = 5), 119 ± 8 %
for α3β1ε (n = 6) and 158 ± 4 % for α3β1εθ (n = 4) recep-BMC Pharmacology 2006, 6:1 http://www.biomedcentral.com/1471-2210/6/1
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tors, indicating that γ2 subunit-containing receptors were
slightly more potentiated by pregnanolone than α3β1
receptors (p < 0.05, Dunnett's test). Nonlinear regression
fit of pregnanolone potentiation of GABA-induced cur-
rents yielded remarkable differences in pregnanolone
potency as α3β1γ2 receptors were highly sensitive and
robustly potentiated by pregnanolone [EC50 47 nM and
maximal potentiation 182 ± 10 % (Fig. 5)]. The α3β1ε,
α3β1 and α3β1θ receptors were apparently much less sen-
sitive (α3β1 receptors had EC50 of 190 nM and in θ and ε
subunit-containing receptors it could not be accurately
estimated due to lack of saturation). The α3β1 and α3β1θ
receptors were clearly potentiated, but there was only little
neurosteroid potentiation in α3β1ε receptors. Interest-
ingly, the addition of both ε and θ subunits appears to
increase the potency and reduce the efficacy as compared
to α3β1θ receptors.
ε and θ subunits do not confer benzodiazepine sensitivity 
nor affect barbiturate modulation
Benzodiazepines presumably bind to the interface
between α and γ2 subunits [24]. In the presence of 1 mM
flurazepam, GABA-induced currents were affected as fol-
lows: 100 ± 3% of the GABA control response (mean ±
standard error, n = 4) in α3β1, 251 ± 31% in α3β1γ2 (n =
4), 107 ± 3% in α3β1θ (n = 3) and 108 ± 6% in α3β1ε (n
= 5) receptors. As expected [25], benzodiazepine sensitiv-
ity was achieved only among the receptor subtype con-
taining the crucial γ2 subunit. Nonlinear regression fit of
flurazepam effects on GABA-induced currents revealed
EC50 = 11.4 µM and maximal potentiation of 254 ± 21%
of the GABA control response in α3β1γ2 receptors (Fig.
6). Possible negative modulation of ε subunit-containing
receptors at low flurazepam concentrations was not statis-
tically significant (p > 0.05, n = 6).
In the presense of 100 µM pentobarbital, GABA-induced
currents were 210 ± 10 % of the control GABA response in
α3β1 (mean ± standard error, n = 5), 308 ± 20 % in
α3β1γ2 (n = 9), 265 ± 9 % in α3β1θ (n = 4) and 190 ± 10
% in α3β1ε (n = 8) receptors, showing that γ2 subunit-
containing receptors were more efficaciously potentiated
by pentobarbital than other combinations (p  < 0.05,
ANOVA), which did not differ from each other.
Direct activation by etomidate and propofol
Anesthetics at high concentrations are known to open the
GABAA receptor ionophores also directly in the absence of
GABA, i.e., without allosteric interaction with the GABA
binding sites [1]. We used etomidate and propofol at high
300 µM non-saturating concentrations, and found that
the α3β1ε, α3β1γ2, α3β1 and α3β1θ receptors were all
slightly activated in the absence of GABA (Fig. 7). Etomi-
date at 300 µM provoked currents from 14.5 % (α3β1θ, n
= 4) up to 46.8% (α3β1ε, n = 4) of EC25 GABA control
responses. Propofol at 300 µM provoked even smaller cur-
rents ranging between 3 % (α3β1θ, n = 5) to 25 %
(α3β1ε) of the EC25 GABA responses. All drugs and GABA
controls were applied to each oocyte. These results indi-
cate that the effects of etomidate and propofol in the pres-
ence of EC25 GABA are not due to direct effects on the
receptor channel, but rather due to allosteric potentiation
of the GABA action.
Discussion
The present data indicate that the locus coeruleus -
enriched ε and θ subunits of GABAA receptors produce sig-
nificant functional and pharmacological changes on the
α3β1 receptors. These features also differentiate them
from γ2 subunit-containing receptors. It is thus possible
that the novel subunits may form receptor populations
that could be selectively targeted by future drugs.
As compared to the α1 subunit-containing receptors, the
α3 subunit receptors display a reduced sensitivity to
GABA, which has been traced to an extracellular N-termi-
nal domain of four amino acids within the α subunits that
mediates the distinct sensitivities to GABA [26]. We con-
firmed here the very low GABA sensitivity in most of the
α3 subunit combinations tested (Fig. 1A), the EC50 values
for GABA being 10–100 times higher than those found in
previous studies in recombinant α1 and especially α6 sub-
unit-containing receptors expressed in oocytes [27]. How-
ever, the ε subunit confers high GABA sensitivity to the
receptors, the EC50 for GABA being almost 100-fold lower
than that for α3β1γ2 receptors. Thus, the ε subunit makes
the α3-receptors as sensitive to the natural transmitter as
most other receptor subtypes are. This effect of ε subunit
may be specifically dependent on the α subunit, since in
α1 subunit-containing receptors the addition of ε does
not alter GABA sensitivity [28]. The high GABA potency of
the α3β1ε receptors was apparently reduced when θ sub-
unit was added. However, whether all subunits were
present in the same pentameric receptors in our condi-
tions remains uncertain and awaits further experiments
with linked subunits.
Previously it has been shown that gaboxadol binds to and
acts on all GABAA receptors with a relatively low selectivity
[29,30]. More recently, gaboxadol has been suggested to
affect more efficiently or potently extrasynaptically
located GABAA  receptors (perhaps α4/5/6βδ subtypes)
[31-34], which are found at high concentrations in the
hippocampus, thalamus and cerebellum, but are also
present widely in the neocortex [35]. Gaboxadol potency
and efficacy are dependent on the α subunit [36,37]. In
the present study, gaboxadol had a low potency at all α3
subunit-containing receptors, but its potency was higher
in the presence of ε subunits than with γ2 subunits (Fig.
1B). However, the potency variation was smaller betweenBMC Pharmacology 2006, 6:1 http://www.biomedcentral.com/1471-2210/6/1
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the subtypes with gaboxadol than with GABA, which
might have something to do with the differences in intrin-
sic efficacies. We found high apparent efficacies for gabox-
adol in most receptor subtypes (Fig. 1), but in comparison
to GABA in the same oocytes, its efficacy was lower than
that of GABA at 1 mM concentrations. This is consistent
with partial agonism of gaboxadol that has previously
been shown for α3β1/2/3γ2 receptors [36].
A feature of the ε subunit-containing receptors was the
spontaneous activity of the chloride channel, which has
been observed in other recombinant receptor experiments
when ε is expressed with α1 and β subunits [28,38,39].
The ε subunit-containing receptors have been suggested to
have higher stability of the energetically more favorable
ionophore open-state position than closed-state position,
functionally causing "leakage" currents [38]. The sponta-
neously active currents can be blocked by GABAA antago-
nists such as picrotoxin (Fig. 2) [39,40]. In line with our
results with α3β1 receptors, agonist sensitivity has been
shown to be increased with the degree of spontaneous
receptor current in α1β2γ2/ε receptors ([40], but see
[28]). The role of constitutive receptor channel activity is
still uncertain, since e.g. Sergeeva and Haas [41] found
that constitutive activity did not correlate with the expres-
sion of ε subunit mRNA in cultured hypothalamic neu-
rons. Thompson et al. [19] have suggested that the relative
level of ε subunit expression may influence the emergence
of constitutive channel activity. At least in recombinant
receptors in vitro, the constitutive activity is the hallmark
of ε subunit-containing receptors.
In our experiments, the ε-containing receptors were
mildly, if at all, modulated by different allosteric agonists
(flurazepam, pregnanolone, etomidate and propofol) in
the presence of GABA, supporting the previous findings
about benzodiazepine-insensitivity and reduced efficacy
of general anesthetics at ε subunit-containing receptors
[17]. Since we applied GABA and the modulators simulta-
neously, part of the response at high modulator concen-
trations could be due to their direct effects. However,
etomidate and especially propofol alone at 300 µM con-
centration caused only small responses in the absence of
GABA, indicating that the main effect of these modulators
was the potentiation of GABA action. Spontaneous open-
ings induced by the ε subunit may decrease the anesthetic
efficacy compared to that in α3β1 dimer subtype,
although the baseline GABA sensitivity differences were
taken into account by adjusting the GABA concentrations
to EC25 of each receptor subtype. Furthermore, the addi-
tion of ε subunit even to the α1β3θ receptors that show
high etomidate and propofol efficacies, reduced the effica-
cies of these drugs. Only the barbiturate pentobarbital
retained its activity in the ε subunit-containing receptors
in our study. Our results are in concert with those of Whit-
ing et al. [42] and Neelands et al. [38], who found barbit-
urate potentiation in α1β1ε and α1β3ε combinations
expressed in oocytes. However, Irnaten et al. [43] found
the cardiac parasympathetic neurons transfected with the
ε subunit to lose their pentobarbital modulation of spon-
taneous IPSCs and pentobarbital-evoked facilitation of
GABAergic currents. It should be noted that the LC neu-
rons from the rat are sensitive to barbiturates using intra-
cellular recording from in vitro brain slices [44], indicating
that the expression of ε subunits in these neurons does not
make the neurons insensitive to barbiturates.
The θ subunit was clearly more silent in various receptor
subunit combinations than the ε subunit. GABA sensitiv-
ity was not altered by inclusion of the θ subunit in α3β1
receptors. Injections of the oocytes with α3 and θ or α3, θ
and ε subunit cRNA cocktails did not produce functional
responses to GABA, although the amino acid sequence
identity of the θ subunit resembles that of the β subunits
[15]. This indicates that the θ subunit fails to fully replace
the β subunits. Pharmacologically the θ subunit brought
about clear properties to α3β1θ receptors, the most strik-
ing being the increased efficacy of the anesthetic etomi-
date (Fig. 3). This is important, since etomidate belongs to
the growing number of GABAA receptor ligands the effi-
cacy of which is largely determined by residues in the sec-
ond transmembrane region of the β subunits [1].
Etomidate is more potent and efficacious on β2 and β3
receptors than on β1 receptors [45,46], which apparently
Constitutive activity of ε subunit-containing receptors Figure 2
Constitutive activity of ε subunit-containing recep-
tors. The ε subunit-containing receptors display spontane-
ous currents that can be blocked with picrotoxin. A. A 
representative current trace recorded from an oocyte 
expressing spontaneously open α3β1ε receptors is shown. 
GABA (30 µM) application induced typical inward currents. 
Picrotoxin (Picro, 100 µM) reversibly blocked spontaneously 
active receptors as shown by blockade (outward current) of 
apparent leakage current. B. Peak amplitudes (in nA given as 
means ± standard errors) of GABA- and picrotoxin-induced 
currents in six oocytes expressing α3β1ε receptors.
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Sensitivities to the anesthetic etomidate Figure 3
Sensitivities to the anesthetic etomidate. Modulation of GABA-induced currents by etomidate in recombinant GABAA 
receptors expressed in Xenopus oocytes. A. Representative traces of etomidate (Etom, µM) modulation of GABA-induced cur-
rents (G, EC25 in µM) in different receptor subtypes. Also the effect of flurazepam at 100 µM is shown for the α3β1γ2 recep-
tors. B. Etomidate dose-response curves in the presence of EC25 GABA (set to 100 %). The values are means ± standard 
errors (n = 6 for α3β1; n = 7 for α3β1γ2; n = 9 for α3β1θ; n = 11 for α3β1ε and n = 4 for α3β1θε receptors).
A.
200 s
5
0
0
n
A
G3 0
Etom 0.1 10 100
     
300
200 s
5
0
0
n
A
G3 0
Etom
Flurazepam 100
30
      
0.1 10 100
200 s
5
0
0
n
A
G 1.5
Etom
     
100 10 0.1
200 s
5
0
0
n
A
G1 6
Etom
    
B.
-8 -7 -6 -5 -4 -3
50
100
150
200
250
300
350
400
 3 1
 3 1 2
 3 1 
 3 1 
 3 1  
log [Etomidate, M]
%
o
f
c
o
n
t
r
o
l
G
A
B
A
r
e
s
p
o
n
s
eBMC Pharmacology 2006, 6:1 http://www.biomedcentral.com/1471-2210/6/1
Page 7 of 12
(page number not for citation purposes)
Sensitivities to the anesthetic propofol Figure 4
Sensitivities to the anesthetic propofol. Modulation of GABA-induced currents by propofol in recombinant GABAA 
receptors expressed in Xenopus oocytes. A. Representative traces of propofol (Prop, µM) modulation of GABA-induced cur-
rents (G, EC25 in µM) in different receptor subtypes. B. Propofol dose-response curves in the presence of EC25 GABA (set to 
100 %). The values are means ± standard errors (n = 6 for α3β1; n = 9 for α3β1γ2; n = 6 for α3β1θ; n = 7 for α3β1ε and n = 
3 for α3β1θε receptors).
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Sensitivities to the neurosteroid pregnanolone Figure 5
Sensitivities to the neurosteroid pregnanolone. Modulation of GABA-induced currents by the neurosteroid pregna-
nolone in recombinant GABAA receptors expressed in Xenopus oocytes. A. Representative traces of pregnanolone (Preg, nM) 
modulation of GABA-induced currents (G, EC25 in µM) in different receptor subtypes. B. Pregnanolone dose-response curves 
in the presence of EC25 GABA (set to 100 %). The values are means ± standard errors (n = 6 for α3β1; n = 5 for α3β1γ2; n = 
5 for α3β1θ; n = 6 for α3β1ε and n = 4 for α3β1θε receptors).
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explains its low efficacy in our α3β1 and α3β1γ2 recep-
tors. Our experiments should be extended to the amino
acid residue level by testing whether the residue in the θ
subunit (Gln), homologous TM II region residue Ser265
in the β1 subunit vs. Asn265 in the β2 and 3 subunits
[46], is responsible for the altered pharmacology. This
might reveal the molecular mechanisms of how θ subu-
nits promote the actions of etomidate in β1 subunit-con-
taining receptors. Our finding might suggest that even β1
subunit-containing receptors may be partially responsible
for the actions of etomidate, when the receptor also har-
bors the θ subunit. This could complicate the conclusions
recently drawn from the studies with mouse lines having
etomidate-insensitive Asn-Ser point-mutated β2 or β3
subunits, with the β2 subunit-containing receptors selec-
tively mediating etomidate sedation and hypothermia
and β3 subunit-containing receptors etomidate hypnosis
and anesthetic immobility [47-50]. However, since the θ
subunit increased only the efficacy of etomidate and
failed to provide the higher potency that β2 and β3 do, the
β1θ subunit-containing receptors might not have a great
influence on the in vivo sensitivity to etomidate.
Propofol efficacy was also high in the presence of the θ
subunit, but now identical to that of the γ2 subunit. Sim-
ilar efficacy profile was found for the neurosteroid pregna-
nolone, but not so clearly for pentobarbital. The θ
subunits are not critical for the actions of benzodi-
azepines, as the GABA potentiation by flurazepam did not
take place in α3β1θ receptors.
Conclusion
Locus coeruleus neurons express a rare repertoire of
GABAA receptor subunits to form GABAA receptor sub-
types with specific characteristics. Our present data sug-
gest that α3β1θ and α3β1ε receptor subtypes, expressed
uniquely in the locus coeruleus, are differentially affected
by benzodiazepines and anesthetics in comparison to
α3β1 and α3β1γ2 receptors. This pharmacological diver-
sity might be exploited to find subtype-selective com-
pounds for the treatment of stress and anxiety, and for the
induction of analgesia and sedation. Furthermore, the ε
subunit confers high transmitter sensitivity, which may
make it a dominant site for physiological modulation,
especially if located in receptors outside synapses.
Methods
All experimental procedures were approved by the Institu-
tional animal use and care committee of the University of
Helsinki.
Recombinant receptor expression in Xenopus oocytes
Capped cRNAs encoding for human GABAA receptor sub-
units α3, β1, γ2S, ε and θ were transcribed in vitro from
pCDM8 plasmids using mMessenger mMachineTM kit
(Ambion Inc., Austin, TX) according to manufacturer's
instructions. The θ and ε clones were from Ewen Kirkness
(The Institute for Genomics Research, Rockville, USA)
and  α3,  β1 and γ2S clones from Paul Whiting (MSD
Research Laboratories, Neuroscience Research Center,
Essex, UK). Oocytes were removed during 0.2 % tric-
ainemethanosulphonate (Sigma, St. Louis, MO) anesthe-
sia from adult female Xenopus laevis frogs (Horst Kähler,
Hamburg, Germany). Isolated oocytes were stored in Nor-
mal Frog Ringer (NFR containing in mM): 115 NaCl, 2.5
KCI, 18 CaCI2 and 10 HEPES; pH 7.5. Oocytes were then
defolliculated manually with forceps and injected with 40
nl of a solution containing mixtures of subunit cRNAs
(0.6 – 2.5 µg/µl) or pure water. Oocyte injections were car-
ried out using a Drummond Nanoject injector (Drum-
mond Scientific Co., Broomall, PA) via a glass
micropipette having the tip diameter of about 17–20 µm.
Subtype-specific cRNA cocktails were mixed beforehand,
cRNA ratios of various subunits were 1:1 for α3β1 recep-
tors,  α3β1γ2S (1:1:10), α3β1θ (1:1:10), α3β1ε (1:1:1)
and α3β1θε (1:1:10:1), one part being equivalent to the
cRNA concentration of 2.5 µg/µl. A lower amount of ε
cRNA than the γ2 and θ cRNA was injected, since higher
amounts caused the oocytes to become leaky and unsuit-
able for electrophysiology. Oocytes were incubated at
18°C in incubation solution (MBS, Modified Barth Solu-
tion, supplemented with 2 mM sodium pyruvate, penicil-
lin 100 U/ml and streptomycin 100 µg/ml). After
injection (two h – one day) oocytes were digested for 30
min in Ca2+- free medium (82.5 mM NaCI, 2.5 mM KCI,
1 mM MgCI2, 1 mM Na2HPO4 and 5 mM HEPES; pH 7.5)
Sensitivities to the barbiturate pentobarbital and the benzo- dizepine flurazepam Figure 6
Sensitivities to the barbiturate pentobarbital and the 
benzodizepine flurazepam. Modulation of GABA-
induced currents by pentobarbital and flurazepam in recom-
binant GABAA receptors expressed in Xenopus oocytes. A. 
Pentobarbital dose-response curves in the presence of EC25 
GABA (set to 100 %). The values are means ± standard 
errors (n = 6 for α3β1; n = 9 for α3β1γ2; n = 4 for α3β1θ 
and n = 8 for α3β1ε receptors). B. Flurazepam dose-
response curves in the presence of EC25 GABA (set to 100 
%). The values are means ± standard errors (n = 6 for α3β1; 
n = 9 for α3β1γ2; n = 4 for α3β1θ and n = 8 for α3β1ε 
receptors).
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containing 0.3 U/ml collagenase type IA (Sigma) in order
to remove additional vitelline membrane surrounding the
oocytes. After enzyme treatment, the oocytes were kept at
18°C in incubation solution until recordings.
Electrophysiological recordings
Electrophysiological recordings were started 18 h after
cRNA injection. Oocytes were perfused with NFR ± drugs
at the flow rate of 1 ml/min in OPC-3 stand chamber
(BioScience Tools, San Diego, US) at room temperature
(22°C) using two-electrode voltage clamp, Ismatec pump
(Ismatec, Glattbrugg-Zürich, Switzerland) and a 17-chan-
nel perfusion system with electronically controlled pinch
valves as described [51]. Drug combinations were mixed
prior to experiments. Oocytes were impaled with two
microelectrodes that had resistance of 1.0–2.5 MΩ when
filled with 3 M KCI plus 10 mM EGTA, and voltage
clamped at -50 mV using Turbo TEC-05 two-electrode
voltage-clamp amplifier (npi Electronics, Tamm, Ger-
many). GABA, flurazepam hydrochloride and sodium
pentobarbital (Sigma) were dissolved in NFR as 10 mM
stock solutions. Etomidate (Sigma) and propofol (Tocris
Cookson, Avonmouth, UK) were dissolved into ethanol
(final concentration < 0.1 %) or dimethylsulphoxide
(DMSO, maximal concentration = 0.3 % by vol.), respec-
tively. 5α-Pregnan-3-α-ol-20-one (Sigma) was prepared
as 10 mM stock in DMSO and maximal final vehicle con-
centration of DMSO was 0.3 % (v/v) which had no effect
alone or on GABA-elicited currents (not shown). The pH
of stock solutions was adjusted to 7.5. Gaboxadol
(4,5,6,7-tetrahydroisoxazolo [5,4-c]pyridin-3-ol; THIP)
was kindly provided by Bjarke Ebert (H. Lundbeck A/S,
Copenhagen, Denmark). Experiments were controlled by
EggWorks experimental control and data acquisition soft-
ware program (version 3.0.2, npi). Drugs were applied for
10 s, and 180–300 s washout periods were used depend-
ing on drug concentrations and receptor sensitivity pro-
files. At least two different batches of oocytes were used to
collect data for each analysis.
Data analysis
Data analysis was performed using EggWorks Reader (ver-
sion 3.0.2, npi) and Prism (version 3.0, GraphPad Soft-
ware, San Diego, CA) programs. The amplitudes of peak
currents were measured from recorded traces, normalized
and presented as a percentage of the control current. The
GABA dose-response curves (using the top and bottom
fixed to 100 and 0, respectively) and some of the drug-
effect curves (no fixed parameters) were analyzed using a
sigmoidal nonlinear regression fit to estimate the EC50
values and maximal efficacies. To compare GABA sensitiv-
ity or drug effects on different GABAA receptor subtypes,
one-way analysis of variance (ANOVA) and Dunnett's
post test were used. The data are given as means ± stand-
ard errors.
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